Works Cited

1. National Collaborating Center for Women's and Children's Health. National Institute for Health and Care Excellence Clinical Guidelines: Heavy Menstrual Bleeding. Available at https://www.nice.org.uk/guidance/qs47. Last accessed August 20, 2018.

2. Curtis MG, Linares ST, Antoniewicz L. Glass' Office Gynecology. 7th ed. Philadelphia, PA: Lipincott Williams & Wilkins; 2014.

3. Emans SJ, Laufer MR. Emans, Laufer, Goldstein's Pediatric and Adolescent Gynecology. 6th ed. Philadelphia, PA: Lipincott Williams & Wilkins; 2012.

4. Tewari D. Invasive Cervical Cancer. Lecture presented at: 32nd Annual Review Course in Clinical Obstetrics and Gynecology; October 20, 2009; Costa Mesa, CA.

5. American College of Obstetricians and Gynecologists Committee on Practice Bulletins. Practice bulletin no. 136: management of abnormal uterine bleeding associated with ovulatory dysfunction. Obstet Gynecol. 2013;122(1):176-185. [Reaffirmed 2018].

6. Gabbe SG, Niebyl FR, Simpson FL, et al. Obstetrics, Normal and Problem Pregnancies. 7th ed. Philadelphia, PA: Elsevier; 2016.

7. Munro MG, Critchley HO, Fraser IS. The FIGO classification of causes of abnormal uterine bleeding. Int J Gynaecol Obstet. 2011;113:3-13.

8. Fraser IS, Critchley HO, Munro MG, Broder M. Can we achieve international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding? Hum Reprod. 2007;22(3):635-643.

9. Lobo RA, Gershenson DM, Lentz GM, Valea FA. Comprehensive Gynecology. 7th ed. Philadelphia, PA: Elsevier Mosby; 2016.

10. American College of Obstetricians and Gynecologists. Alternatives to hysterectomy in the management of leiomyomas. Obstet Gynecol. 2008;112(2 pt 1):387-400.

11. Vuchinich KM. Abnormal Uterine Bleeding/Fibroids. Lecture presented at: 32nd Annual Review Course in Clinical Obstetrics and Gynecology; October 17, 2009; Costa Mesa, CA.

12. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188(1):100-107.

13. Marjoribanks J, Lethaby A, Farquhar C. Surgery versus medical therapy for heavy menstrual bleeding. Cochrane Database Syst Rev. 2016;1:CD003855.

14. Marshall LM, Spiegelman D, Goldman MB, et al. A prospective study of reproductive factors and oral contraceptive use in relation to the risk of uterine leiomyomata. Fertil Steril. 1998;70(3):432-439.

15. Mercorio F, De Simone R, Di Spiezio Sardo A, et al. The effect of a levonorgestrel-releasing intrauterine device in the treatment of myoma-related menorrhagia. Contraception. 2003;67(4):277-280.

16. American College of Obstetricians and Gynecologists. The role of transvaginal ultrasonography in the evaluation of postmenopausal bleeding. Obstet Gynecol. 2009;113(2 pt 1):462-464.

17. Chi DS, Berchuck A, Dizon DS, Yashar CM (eds). Principles and Practice of Gynecologic Oncology. 7th ed. Philadelphia, PA: Lipincott Williams & Wilkins; 2017.

18. Fritz MA, Speroff L. Clinical Gynecologic Endocrinology and Infertility. 8th ed. Baltimore, MD: Lipincott Williams & Wilkins; 2012.

19. Randall L. Endometrial Cancer. Lecture presented at: 32nd Annual Review Course in Clinical Obstetrics and Gynecology; October 20, 2009; Costa Mesa, CA.

20. Baker J, Obermair A, Gebski V, Janda M. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol. 2012;125(1):263-270.

21. Moayeri SE. Polycystic Ovary Syndrome. Lecture presented at: 32nd Annual Review Course in Clinical Obstetrics and Gynecology; October 16, 2009; Costa Mesa, CA.

22. National Cancer Institute. SEER Cancer Statistics Review, 1975–2012. Available at https://seer.cancer.gov/csr/1975_2012/sections.html. Last accessed August 20, 2018.

23. DeVore GR, Owens O, Kase N. Use of intravenous Premarin in the treatment of dysfunctional uterine bleeding: a double-blind randomized controlled study. Obstet Gynecol. 1982;59(3):285-291.

24. Cooper J, Gimpelson R, Laberge P. A randomized, multicenter trial of safety and efficacy of the NovaSure system in the treatment of menorrhagia. J Am Assoc Gynecol Laprosc. 2002;9(4):418-428.

25. Sabbah R, Desaulniers G. Use of the NovaSure Impedance Controlled Endometrial Ablation System in patients with intracavitary disease: 12-month follow-up results of a prospective, single-arm clinical study. J Minim Invasive Gynecol. 2006;13(5):467-471.

26. Kafy S, Huang JY, Al-Sunaidi M, Wiener D, Tulandi T. Audit of morbidity and mortality rates of 1792 hysterectomies. J Minim Invasive Gynecol. 2006;13(1):55-59.

27. Shavell VI, Diamond MP, Senter JP, Kruger ML, Johns DA. Hysterectomy subsequent to endometrial ablation. J Minim Invasive Gynecol. 2012;19(4):459-464.

28. Oriel KA, Schrager S. Abnormal uterine bleeding. American Family Physician. 1999;60(5):1371-1382.

29. Spies JB, Bruno J, Czeyda-Pommershein F, et al. Long-term outcome of artery embolization of leiomyomata. Obstet Gynecol. 2005;106(5 pt 1):933-939.

30. National Cancer Institute. Cervical Cancer Screening (PDQ). Available at https://www.cancer.gov/types/cervical/hp/cervical-screening-pdq#section/all. Last accessed August 20, 2018.

31. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137.

32. American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Committee on Gynecologic Practice. Committee Opinion No. 580: von Willebrand disease in women. Obstet Gynecol. 2013;122(6):1368-1373.

33. Senol T, Kahramanoglu I, Dogan Y, Baktiroglu M, Karateke A, Suer N. Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma. Clin Exp Obstet Gynecol. 2015;42(2):224-227.

34. Kudesia R, Singer T, Caputo TA, et al. Reproductive and oncologic outcomes after progestin therapy for endometrial complex atypical hyperplasia or carcinoma. Am J Obstet Gynecol. 2014;210(3):255.e1-e4.

35. Office on Women's Health. Polycystic Ovary Syndrome. Available at https://www.womenshealth.gov/a-z-topics/polycystic-ovary-syndrome. Last accessed August 20, 2018.

36. National Cancer Institute. SEER Stat Fact Sheets: Endometrial Cancer. Available at https://seer.cancer.gov/statfacts/html/corp.html. Last accessed August 20, 2018.

37. American College of Obstetricians and Gynecologists Committee on Adolescent Health Care, Committee on Gynecologic Practice. Committee opinion no. 557: management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Obstet Gynecol. 2013;121(4):891-896.

38. Lethaby A, Duckitt K, Farquhar C. Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding. Cochrane Database Syst Rev. 2013:31;1:CD000400.

39. Lipscomb GH. Endometrial Ablation. Available at http://www.glowm.com/section_view/heading/Endometrial%20Ablation/item/24. Last accessed August 20, 2018.

40. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of uterine myomas: a review. Int J Fertil Steril. 2016;9(4):424-435.

41. Zhang Q, Qi G, Kanis MJ, Dong R, Cui B, Yang X, Kong B. Comparison among fertility-sparing therapies for well differentiated early-stage endometrial carcinoma and complex atypical hyperplasia. Oncotarget. 2017;8(34):57642-57653.

42. Williams T, Mortada R, Porter S. Diagnosis and treatment of polycystic ovary syndrome. Am Fam Physician. 2016;94(2):106-113.

43. Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr Pract. 2015;21(11):1291-1300.

44. Goodman NF, Cobin RH, Futterweit W, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 2. Endocr Pract. 2015;21(12):1415-1426.

45. U.S. Food and Drug Administration. FDA Releases New Findings on the Risks of Spreading Hidden Uterine Cancer through the Use of Laparoscopic Power Morcellators. Available at https://www.fda.gov/newsevents/newsroom/fdainbrief/ucm589137.htm. Last accessed September 10, 2018.

46. American College of Obstetricians and Gynecologists.Committee Opinion 532: Compounded Bioidentical Menopausal Hormone Therapy. Available at https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Gynecologic-Practice/Compounded-Bioidentical-Menopausal-Hormone-Therapy. Last accessed September 10, 2018.

Evidence-Based Practice Recommendations Citations

1. Khati NJ, Glanc P, Bhosale PR, et al. ACR Appropriateness Criteria: Abnormal Vaginal Bleeding. Reston, VA: American College of Radiology; 2014. Available at https://acsearch.acr.org/docs/69458/Narrative. Last accessed August 21, 2018.

2. North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of the North American Menopause Society. Menopause. 2013;20(9):888-902. Available at https://www.menopause.org/docs/default-source/2013/vva-position-statement.pdf. Last accessed August 21, 2018.

3. American College of Obstetricians and Gynecologists. Endometrial Ablation. Washington, DC: American College of Obstetricians and Gynecologists; 2007, 2018. Available at https://journals.lww.com/greenjournal/Citation/2007/05000/ACOG_Practice_Bulletin_No__81__Endometrial.43.aspx. Last accessed August 21, 2018.


Copyright © 2018 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.